2023 was a year of challenge and change, both in the world and at Lonza. We have seen high interest rates, persistent inflation, supply chain disruptions, wars in Ukraine and the Middle East, growing geopolitical tensions, and the continuing challenges of climate change. However, corporate investments remained solid, harnessing innovation and technology to address the challenges of the future.
Employees
(Full-time equivalent)
CORE EBITDA in CHF
New CDMO programs signed
Global development and manufacturing sites
CORE EBITDA margin in %
Trademark filings
Sales in CHF
Brands
New CDMO customers
Sales growth in %1
Small2 and large3 molecules
ROIC in %
CDMO customers4
Active patent families
Constant exchange rate (CER); in actual exchange rate (AER) +7.9%
Including active pharmaceutical ingredients (API), highly potent API (HPAPI), dosage form and delivery systems and particle engineering
Including mammalian, microbial, bioconjugates, drug product services and cell and gene therapy products (personalized medicines are included in pre-clinical and clinical molecules only, early development services are included for pre-clinical molecules only)
Based on distinct companies
Our capacity to deliver long-term value is supported by our strong balance sheet and our sustained approach to organic growth investments to meet customer needs.
Across our site network, we deliver value for our customers through our combined focus on quality, safety and operational excellence.
Sustainability is a key aspect of value creation, alongside quality and efficiency. It is integrated into our business strategy, and supported by clear delivery targets in our remuneration policies.
Our people are our greatest asset. Taken together, their talent, dedication and hard work bring to life our purpose to enable a healthier world.
In Small Molecules, we continue to adapt our capabilities and commercial offerings aligned with market needs, further augmented with additional capacity to meet sustained customer demand, particularly supporting highly potent API products. Looking ahead, we will continue to focus on the acquisition of early-phase clinical projects to help drive future growth.
In Biologics, we continued to build our pipeline, strengthened our manufacturing network, in particular for ADCs, and built our technology portfolio with the acquisition of Synaffix. We signed multiple dedicated long-term customer programs, which reflect the value of our offerings. 2024 was our strongest signing year on record.
In Cell & Gene, we celebrated the groundbreaking of a new cell therapy manufacturing facility in Portsmouth (US) to support the development and commercialization of the Vertex type 1 diabetes cell therapy portfolio.
In Capsules & Health Ingredients, we improved customer satisfaction and advanced our innovation roadmap. We advanced the development of our next-generation hard empty capsule manufacturing technology and extended our proprietary capsule sealing technology to additional polymer formulations.
